Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase
- 2 February 2021
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 22 (3), 516-522
- https://doi.org/10.1002/cbic.202000298
Abstract
Indoleamine-2,3-dioxygenase 1 (IDO1) is a heme-containing enzyme that catalyzes the rate-limiting step in the kynurenine pathway of tryptophan (TRP) metabolism. As it is an inflammation-induced immunoregulatory enzyme, pharmacological inhibition of IDO1 activity is currently being pursued as a potential therapeutic tool for the treatment of cancer and other disease states. As such, a detailed understanding of the mechanism of action of IDO1 inhibitors with various mechanisms of inhibition is of great interest. Comparison of an apo-form-binding IDO1 inhibitor (GSK5628) to the heme-coordinating compound, epacadostat (Incyte), allows us to explore the details of the apo-binding inhibition of IDO1. Herein, we demonstrate that GSK5628 inhibits IDO1 by competing with heme for binding to a heme-free conformation of the enzyme (apo-IDO1), whereas epacadostat coordinates its binding with the iron atom of the IDO1 heme cofactor. Comparison of these two compounds in cellular systems reveals a long-lasting inhibitory effect of GSK5628, previously undescribed for other known IDO1 inhibitors. Detailed characterization of this apo-binding mechanism for IDO1 inhibition might help design superior inhibitors or could confer a unique competitive advantage over other IDO1 inhibitors vis-a-vis specificity and pharmacokinetic parameters.This publication has 57 references indexed in Scilit:
- Human Indoleamine 2,3-Dioxygenase Is a Catalyst of Physiological Heme Peroxidase Reactions: IMPLICATIONS FOR THE INHIBITION OF DIOXYGENASE ACTIVITY BY HYDROGEN PEROXIDEJournal of Biological Chemistry, 2013
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic PerspectivesClinical Cancer Research, 2011
- Bringing chemistry to lifeNature Methods, 2011
- Drug-Induced Regulation of Target ExpressionPLoS Computational Biology, 2010
- Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T H 17 to Regulatory T Cells in HIV DiseaseScience Translational Medicine, 2010
- The Selenazal Drug Ebselen Potently Inhibits Indoleamine 2,3-Dioxygenase by Targeting Enzyme Cysteine ResiduesBiochemistry, 2009
- Application of high-throughput affinity-selection mass spectrometry for screening of chemical compound libraries in lead discoveryExpert Opinion on Drug Discovery, 2007
- Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-DioxygenaseThe Journal of Experimental Medicine, 2002
- Inhibition of Nitric Oxide Synthase Expression and Activity in Macrophages by 3-Hydroxyanthranilic Acid, a Tryptophan MetaboliteArchives of Biochemistry and Biophysics, 1997
- Reconstitution of myoglobin from apoprotein and heme, monitored by stopped‐flow absorption, fluorescence and circular dichroismJBIC Journal of Biological Inorganic Chemistry, 1988